Wallace et al. Dose, duration, recency dependent relationship between GC and MACE. Even 5mg/day, 30 day use, and use 1 year prior associated with risk. 5mg, 7.5mg, 10mg pred for 90 days - 13%, 19%, 27% MACE increase Abstr#2430 #ACR23 #ACRbest @RheumNow https://t.co/50B5nGqxu9 https://t.co/lNrUbZOm0o

A#2429 #ACR23 @RheumNow ROMO v DEN - 12 mo RCT 70 GIOP pts at high-risk Mean prednisolone dose 6.6 mg H/o fragility fx in 1/2 pts 12 mo: Increase in spine BMD- ROMO (+7) and DEN (+2) Hip and Femoral neck improved both (1.6% both), not signif diff bw grps AEs: incr injxn site rxn https://t.co/VueuZIjFfM

Who knew @FDA_Drug_Info presented #ACR23 posters?! I thought they just issue statements if there was information to be shared! Abst#1822 Bari and Toci use during the pandemic for #COVID19 did not show new safety signals. 1 case HBV reactivation with bari @RheumNow https://t.co/zd7TELsV2j

Important data re:ADVOCATE study and health related quality of life Interesting question: is this due to AVA or just simply giving less steroids? I discuss this on recent podcast: https://t.co/7Jm6ArFpsB @RheumNow #ACR23 https://t.co/53T1p2Vvyb

Interesting counterpoint to a tweet from a few days ago re:black box warning for JAKs No change in utilization rates post black box... maybe people had already baked this into the cake by then? @RheumNow #ACR23 Abstr 2142 https://t.co/K9cWbRSWV6

#ACR23 Late-Breaking Abstr#L09 In a crowded market, you’ve got to stand out. Phase 2 RCT of LNK01001, a highly selective JAK1-i in China: improvement in ACR 20,50,70 vs PBO at WK12. Those in PBO who didn’t meet ACR20 improved after receiving Tx. Very low infections @RheumNow https://t.co/ZbJFNHOtFT

Great summary of the big takeaways yesterday at #ACR23. Always love talking to @KDAO2011 @EBRheum @RheumNow We get into the use of MTX, the safety on TNFs and what is in the purview of rheumatology practice https://t.co/jm0a8ndrsi

Excellent pragmatic RCT, TNF withdrawal in RA Almost 2/3 flared by 1 yr; at 3 years up to 3 in 4 Supports my practice of generally continuing TNFs long term Also highlights importance of pt preferences; 1 in 4 may do well if they wish to discontinue @RheumNow #ACR23 #ACRBest https://t.co/G4l0DgBP2Z

#ACR23 Abs #2548 showed incidence rate of uveitis TEAEs was lower to Wk 16 in axSpA pts randomized to BKZ 160 mg Q4W vs PBO. https://t.co/kBLQnJbTU2 @rheumnow https://t.co/regYgvvCts